Short Versus Long Duration of Therapy for Streptococcus Pneumoniae Bloodstream Infections
1 other identifier
observational
200
1 country
1
Brief Summary
Streptococcus pneumoniae is a gram-positive (GP) bacteria responsible for common infections such as community-acquired pneumonia (CAP), as well as complicated infections such as bacteremia, infective endocarditis and meningitis. S. pneumoniae bacteremia ranks among the top 10 most common pathogens associated with bloodstream infections and correlates with high morbidity and mortality worldwide.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 23, 2023
CompletedFirst Submitted
Initial submission to the registry
October 17, 2023
CompletedFirst Posted
Study publicly available on registry
October 23, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 23, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 23, 2026
July 4, 2025
July 1, 2025
3 years
October 17, 2023
July 1, 2025
Conditions
Outcome Measures
Primary Outcomes (3)
Infection related-hospitalization
hospital readmission with streptococcal pneumonia, bacteremia, endocarditis, meningitis, and lung abscess within 30 days of antibiotic completion
30 days
Recurrence
Reinfection with streptococcal pneumonia, within 30 days of antibiotic completion
30 days
All-cause mortality
Death within 30 days of antibiotic completion
30 days
Secondary Outcomes (5)
ICU Length of stay(LOS)
30 days
Hospital LOS
30 days
Occurrence of C. difficile infection
30 days
Total antibiotic treatment duration
30 days
Central venous catheter placement
30 days
Interventions
To evaluate the effectiveness of short 10 days versus long (≥10 days) duration of therapy associated with S. pneumoniae bacteremia.
Eligibility Criteria
Patients ≥18 years of age * S. pneumoniae isolated from ≥1 blood cultures * Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8) * Clinical stability by day 10 of therapy
You may qualify if:
- ≥18 years of age
- S. pneumoniae isolated from ≥1 blood cultures
- Active IV antibiotic therapy within 48 hours of the first positive blood culture(7,8)
- Clinical stability by day 10 of therapy
You may not qualify if:
- Treatment duration \<5 days or \>16 days
- Death before completion of therapy (\<10 days vs. ≥ 10 days )
- Polymicrobial BSI
- Invasive infection caused by S. pneumoniae (endocarditis, meningitis, and lung abscess)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Methodist Dallas Medical Center
Dallas, Texas, 75203, United States
Study Officials
- PRINCIPAL INVESTIGATOR
Matthew Crotty, PharmD
Methodist Midlothian Medical Center
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2023
First Posted
October 23, 2023
Study Start
June 23, 2023
Primary Completion (Estimated)
June 23, 2026
Study Completion (Estimated)
June 23, 2026
Last Updated
July 4, 2025
Record last verified: 2025-07
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
- Time Frame
- 2 years
- Access Criteria
- Clinical Trials portal
The PI is committed to disseminate research results in a timely fashion. Sharing of data generated by this project will be carried out through presentation at scientific meetings and/or publication in Open Access Journals.